Cybin Earns Notice Of Allowance For CYB004

Cybin (CYBN) was recently awarded a Notice of Allowance for it CYB004 deuterated psychedelic tryptamine used to treat anxiety disorders. 

Category Press Release
Country Canada

Companies Featured

Cybin is a for-profit company that aims to deliver psychedelics (psilocybin) via a sublingual delivery mechanism. The company aims to start clinical trials within the year (2021). It has raised $98 million US.